Radiotherapy as metastasis-directed therapy for oligometastatic prostate cancer

Elise De Bleser, Phuoc T. Tran, Piet Ost

Research output: Contribution to journalReview articlepeer-review

25 Scopus citations


Purpose of review To summarize the available literature regarding radiotherapy as a metastasis-directed therapy (MDT) in the treatment of oligometastatic prostate cancer (PCA). Recent findings Three different clinical scenarios of oligometastatic PCA exist in which MDT can be applied: de novo oligometastatic PCA, oligorecurrent PCA, and oligoprogressive PCA. A cut off of three to five metastatic lesions is most often used in these settings. Data from retrospective studies, treating over 1000 patients in total, have been reported. The median progression-free survival ranges between 1 and 3 years, but is influenced by a heterogeneous use of androgen deprivation therapy. For lymph node metastases, a propensity scored matched analysis suggests that cancer specific and overall survival is improved with MDT over standard of care. MDT treatment regimens vary with different radiotherapy techniques, doses, and volumes. Adverse events are limited to grade 1-2 and only rarely grade 3 events are reported. Summary Based on data from retrospective studies, progression-free survival following MDT for oligometastatic PCA is promising with few adverse events. Comparative prospective studies are under way and will shed light on the future of MDT.

Original languageEnglish (US)
Pages (from-to)587-595
Number of pages9
JournalCurrent Opinion in Urology
Issue number6
StatePublished - Nov 1 2017


  • oligometastases
  • prostate cancer
  • stereotactic body radiotherapy
  • whole pelvis radiotherapy

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Radiotherapy as metastasis-directed therapy for oligometastatic prostate cancer'. Together they form a unique fingerprint.

Cite this